FAKTOR-ZERTIFIKAT - VERTEX PHARMACEUTICALS | Market Closed - Börse Stuttgart 14:57:40 2024-06-25 EDT | ||
| 0.36 EUR | +2.86% |
|
| Current month | -45.45% | ||
| 1 month | -47.83% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-06-25 | 0.36 | +2.86% |
| 24-06-24 | 0.35 | -12.50% |
| 24-06-21 | 0.4 | +2.56% |
| 24-06-20 | 0.39 | -9.30% |
| 24-06-19 | 0.43 | +4.88% |
Delayed Quote Börse Stuttgart
Last update June 25, 2024 at 02:57 pm
More quotesStatic data
| Product type | Productos Exóticos |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | J.P. Morgan |
| WKN | JK2J1V |
| ISIN | DE000JK2J1V7 |
| Date issued | 2024-02-23 |
| Strike | 522.4 $ |
| Maturity | Unlimited |
| Parity | 135.45 : 1 |
| Emission price | 2.53 € |
| Emission volume | N/A |
| Settlement | Por diferencias |
| Currency | EUR |
Technical Indicators
| Highest since issue | 4.35 € |
|---|---|
| Lowest since issue | 0.3 € |
| Spread | 0.03 € |
| Spread % | 7.69% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
473.8
USD
Average target price
465.5
USD
Spread / Average Target
-1.75%
- Stock Market
- Certificates
- Certificat
